


December 21, 2012

Terumo Announces Strategic Alliance with Chinese AngioCare in Renal Denervation Technology for Hypertension Treatment

Tokyo — Terumo Corporation (TSE: 4543 Section 1) today announced that a strategic alliance has been formed with Shanghai AngioCare Medical Technology Co., Ltd. (hereinafter “AngioCare”) (Representative: Philip Wang), a Chinese company in renal denervation technology for resistant hypertension treatment. Terumo will take on a 20% share in AngioCare. Furthermore, Terumo will consign product development to AngioCare and acquire the exclusive distribution rights for its renal denervation technology on the global market.

1. Renal denervation

The renal sympathetic nerve plexus is a major contributor of hypertension. During renal denervation, a catheter is introduced using standard interventional technique via the femoral artery, and is positioned in the renal artery under fluoroscopic guidance. The electrode at the distal tip of the catheter delivers high radio frequency through the wall of renal artery to ablate or disrupt the surrounding renal sympathetic nerves lying in the vessel. Renal denervation using a catheter-based technique is highly expected to be a new, effective treatment option for the many patients with hypertension who do not respond to conventional drugs, or “resistant hypertension”. In China, approximately 230 million people are currently suffering from hypertension. Among them, 5.4 million are candidates for renal denervation and the number of such patients is expected to reach approximately 7.2 million by 2025.




2. Objectives of alliance

Terumo has formulated key strategic themes of further promoting business localization and partnership with local companies in China. The alliance in this press release is a part of the mentioned key strategic themes. By entering Chinese renal denervation market with the first domestically manufactured product, Terumo aims for further expansion of its Chinese interventional systems business which offers great future opportunity. Terumo expects it will start sales of its renal denervation system in fiscal year 2015 and aims to achieve around 20% of share in Chinese market, which size is expected to reach over 50 billion yen by year 2020. As for sales outside China, Terumo will conduct a further examination of the opportunity.

The mentioned alliance is not expected to have an impact on business results for the current fiscal year.

3. Outline of alliance



4. Overview of the alliance partner

Name	Shanghai AngioCare Medical Technology Co., Ltd.	
Head Office	590 Ruiqing Rd, Building 6, Suite 301, East Zhangjiang Hi-Tech Park, Shanghai, China	
Representative	Philip Wang	
Establishment	2011	
No. of Employee	15	
Main Activities	The development and production of renal denervation technology	
Capital		
(Before investment)	Approximately 52 million yen (RMB 4 million)	
(After investment)	Approximately 65 million yen (RMB 5 million)	
Ownership	Terumo (China) Holding Co., Ltd.	20%
	Shanghai AngioCare Medical Technology Co., Ltd.	80%

(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.